{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00405457",
      "orgStudyIdInfo": {
        "id": "5261"
      },
      "organization": {
        "fullName": "Innovative Medical",
        "class": "INDUSTRY"
      },
      "briefTitle": "Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms",
      "officialTitle": "Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms"
    },
    "statusModule": {
      "statusVerifiedDate": "2010-02",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2006-11"
      },
      "primaryCompletionDateStruct": {
        "date": "2008-01",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2008-01",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2006-11-28",
      "studyFirstSubmitQcDate": "2006-11-28",
      "studyFirstPostDateStruct": {
        "date": "2006-11-30",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2010-02-19",
      "lastUpdatePostDateStruct": {
        "date": "2010-02-22",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "oldNameTitle": "David Hardten, MD",
        "oldOrganization": "Minnesota Eye Consultants"
      },
      "leadSponsor": {
        "name": "Innovative Medical",
        "class": "INDUSTRY"
      }
    },
    "descriptionModule": {
      "briefSummary": "To evaluate the efficacy, safety and tolerability of a combination of Optive® Artificial Tears with Restasis®.The primary hypothesis is that the Ocular Surface Disease Index (OSDI) score and symptoms will be the same or lower than baseline after treatment in these patients. The patients will tolerate the combination of Restasis® and Optive® with a low incidence of clinical adverse events."
    },
    "conditionsModule": {
      "conditions": [
        "Dry Eye"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 50,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "A",
          "type": "OTHER",
          "interventionNames": [
            "Drug: Restasis, Optive Tears"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Restasis, Optive Tears",
          "description": "Restasis and Optive Tears use twice daily more frequently if needed",
          "armGroupLabels": [
            "A"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "efficacy",
          "timeFrame": "1 yr 3 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "dry eye symptoms",
          "timeFrame": "1 yr 3 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* · Males or females \\> 18 years old\n\n  * Patients currently taking Restasis® for at least 3 months in duration and using artificial tears as needed for dry eye.\n  * Likely to complete all study visits and able to provide informed consent\n\nExclusion Criteria:\n\n* · Patients using Restasis® for less than 3 months.\n\n  * Known contraindications to any study medication or ingredients\n  * Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.\n  * Other active uncontrolled ocular diseases or uncontrolled systemic disease",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "David Hardten, MD",
          "affiliation": "Minnesota Eye Consultants",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Minnesota Eye Consultants",
          "city": "Minneapolis",
          "state": "Minnesota",
          "zip": "55404",
          "country": "United States",
          "geoPoint": {
            "lat": 44.97997,
            "lon": -93.26384
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D015352",
          "term": "Dry Eye Syndromes"
        }
      ],
      "ancestors": [
        {
          "id": "D007766",
          "term": "Lacrimal Apparatus Diseases"
        },
        {
          "id": "D005128",
          "term": "Eye Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D003524",
          "term": "Cyclosporins"
        }
      ],
      "ancestors": [
        {
          "id": "D010456",
          "term": "Peptides, Cyclic"
        },
        {
          "id": "D047028",
          "term": "Macrocyclic Compounds"
        },
        {
          "id": "D011083",
          "term": "Polycyclic Compounds"
        },
        {
          "id": "D010455",
          "term": "Peptides"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        }
      ]
    }
  },
  "hasResults": false
}